XML 115 R74.htm IDEA: XBRL DOCUMENT
v3.23.2

Research and License Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Apr. 06, 2023 | Mar. 29, 2023 | Feb. 21, 2023 | Feb. 28, 2019 | Sep. 30, 2018 | Dec. 31, 2016 | Mar. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Dr. Langer |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
Payment to director |  |  |  |  |  |  |  | $ 11 | $ 6
MIT |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
Description of future development obligations |  |  |  |  |  |  |  | The Company’s future development obligations are: (i) to commence a Phase 3 clinical trial for such Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such Product, and (iii) to make a first commercial sale of such Product within 11 years of the IND filing for such Product. |
License fee payment |  |  |  |  |  | $ 50 |  |  |
Percentage of shares of common stock issued |  |  |  |  |  | 5.00% |  |  |
Description of conditions to terminate license agreement |  |  |  |  |  |  | The Company has the right to terminate for any reason upon a 3-month prior written notice. | The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. |
Right to terminate agreement upon prior written notice |  |  |  |  |  | 3 months |  |  |
Right to terminate agreement if breach remains uncured |  |  |  |  |  | 90 days |  |  |
Right to terminate agreement incase of nonpayment |  |  |  |  |  | 30 days |  |  |
Right to terminate agreement upon prior written notice if insolvent | 3 months |  |  |  |  |  |  |  |
MIT | Maximum |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 2,900 |  |  |
MIT | Patent License Agreement |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
License agreement entered date |  |  |  |  |  | 2016-12 |  |  |
CALIBR |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
License fee payment |  |  |  |  | $ 1,000 |  |  |  |
Percentage of Royalty on Sublicense Revenue |  |  |  |  | 50.00% |  |  |  |
Milestone payments |  |  |  |  | $ 26,000 |  |  |  |
Description of conditions to terminate license agreement |  | the Company sent CALIBR a notice stating that the Company would be terminating the CALIBR License Agreement in 30 days’ time. |  |  |  |  |  | The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. |
Right to terminate agreement if breach remains uncured |  | 30 days |  |  | 30 days |  |  |  |
Right to terminate licensed patents upon prior written notice |  |  |  |  | 90 days |  |  |  |
CALIBR | Patent License Agreement |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
License agreement entered date |  |  |  |  | 2018-09 |  |  |  |
MEE |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
License fee payment |  |  |  | $ 20 |  |  |  |  |
Description of conditions to terminate license agreement |  |  | the Company sent MEE a notice stating that the Company would be terminating the MEE License Agreement in 30 business days’ time. |  |  |  |  | The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days |
Right to terminate agreement upon prior written notice |  |  |  | 30 days |  |  |  |  |
Right to terminate agreement if breach remains uncured |  |  | 30 days | 60 days |  |  |  |  |
Right to terminate agreement incase of nonpayment |  |  |  | 30 days |  |  |  |  |
Right to terminate agreement upon prior written notice if insolvent |  |  |  | 45 days |  |  |  |  |
MEE | Maximum |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  | $ 350 |  |  |  |  |
Annual License Fee Per Share |  |  |  |  |  |  | $ 7.5 | $ 7.5 |
MEE | Minimum |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
Royalty Expense Per Share |  |  |  |  |  |  |  | 15 |
Annual License Fee Per Share |  |  |  |  |  |  | $ 5 | $ 5 |
MEE | Non-Exclusive Patent License Agreement |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |
License agreement entered date |  |  |  | 2019-02 |  |  |  |  |

X
- Definition Annual License Fee Per Share + References No definition available. + Details
Name: | freq_AnnualLicenseFeePerShare
Namespace Prefix: | freq_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of conditions to terminate license agreement. + References No definition available. + Details
Name: | freq_DescriptionOfConditionsToTerminateLicenseAgreement
Namespace Prefix: | freq_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of future development obligations. + References No definition available. + Details
Name: | freq_DescriptionOfFutureDevelopmentObligations
Namespace Prefix: | freq_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement entered date. + References No definition available. + Details
Name: | freq_LicenseAgreementEnteredDate
Namespace Prefix: | freq_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition License fee payment. + References No definition available. + Details
Name: | freq_LicenseFeePayment
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments. + References No definition available. + Details
Name: | freq_MilestonePayments
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of royalty on sublicense revenue. + References No definition available. + Details
Name: | freq_PercentageOfRoyaltyOnSublicenseRevenue
Namespace Prefix: | freq_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of shares of common stock issued. + References No definition available. + Details
Name: | freq_PercentageOfSharesOfCommonStockIssued
Namespace Prefix: | freq_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate agreement if breach remains uncured. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementIfBreachRemainsUncured
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate agreement incase of nonpayment. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementIncaseOfNonpayment
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate agreement upon prior written notice. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementUponPriorWrittenNotice
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate agreement upon prior written notice if insolvent. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate licensed patents upon prior written notice. + References No definition available. + Details
Name: | freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Expense Per Share + References No definition available. + Details
Name: | freq_RoyaltyExpensePerShare
Namespace Prefix: | freq_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17 + Details
Name: | us-gaap_PaymentForManagementFee
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=freq_MassachusettsEyeAndEarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |